Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Cymbalta Prescribers for Neuropathic Pain (US)

Articles with lock require a subscription to GLG News | Request a free trial
February 4, 2008
Galvus Receives Approval, But A Larger Battle Remains
Analysis of: Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com
Author: GLG Expert Contributor
Galvus receives European approval, but has significant barriers for prescribing. This places Galvus significantly behind Januvia as a diabetes treatment option
January 30, 2008
Geographic Location Key In Walk-In Clinic Locations
Analysis of: Operator of Walk-In Clinics Shuts 23 Located in Wal-Mart Stores | www.nytimes.com
Author: GLG Expert Contributor
It is important to understand that geographic placement of these clinics is important.  I think these clinics will continue to pop up until the industry feels out exactly where the market is.  We are located in the southwest suburbs of Chicago, and there are many of these clinics which are...
Daniel WynnJanuary 18, 2008
Major Win For Glaxo with Xenoport for Restless Legs syndrome -- Next Blockbuster?
Analysis of: GlaxoSmithKline and XenoPort report positive top-line results of second phase 3 restless legs syndrome trial for XP13512/GSK1838262 | www.pipelinereview.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Xenoport's trial for XP13512 in restless legs syndrome (RLS) shows strongly positive 9 month data in second phase 3  trial, should be a major win in the marketplace.  RLS represent a major unmet need, for drugs with sustained efficacy and high tolerability.
October 11, 2007
Bogus
Analysis of: Burden of diabetes care rivals disease complications | www.reuters.com
Author: GLG Expert Contributor
No implications, except how these patients are receiving intensive insulin therapy may need to be improved.
September 26, 2007
Another "cure" for diabetes?
Analysis of: Bariatric surgery - possible treatment for type 2 diabetes mellitus | www.news-medical.net
Author: GLG Expert Contributor
1. Weight loss may improve carbohydrate metabolism in patients with  Type 2 DM 2. Weight loss is difficult to maintain even in these patients 3. There is more to curing type 2 DM then losing weight
September 26, 2007
Accomplia: Does it accomplish enough?
Analysis of: Sanofi aims to show there's still life in Acomplia | www.reuters.com
Author: GLG Expert Contributor
Weight loss is good but the amount and time to reach goal is more important then just the weight loss potential itself
September 21, 2007
Exubera: To Little , Too Late
Analysis of: New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years | www.pipelinereview.com
Author: GLG Expert Contributor
Long term studies of Exubera do little to reassure the product's safety. This is especially true in the face of new insulin pens that are safe, effective and makes it very easy to administer insulin.
September 7, 2007
Liraglutide is a small step forward, but there will be bigger steps to come shortly.
Analysis of: Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients | www.pipelinereview.com
Author: GLG Expert Contributor
Liraglutide will steal some market share from the leader, exenatide, but if exenatide comes out in a once a week formulation and other similar products even less often, the market will shift again.
September 3, 2007
Mitiglinide—Thrice Your Out
Analysis of: Elixir Pharmaceuticals initiates final Phase III clinical study prior to NDA | www.pipelinereview.com
Author: GLG Expert Contributor
Mitiglinide may have a role in specific subtypes of diabetes patients, but it thrice a day dosing in a hurdle for all but the compulsive few.
September 3, 2007
Diabetes Medications Are For Sugars; Statins and Hypertensives Are For Hearts
Analysis of: FDA Adviser Questions Surrogate Endpoints for Diabetes Drug Approvals | www.medpagetoday.com
Author: GLG Expert Contributor
To demand diabetes medications have positive outcomes would be akin to asking for proof that antibiotics save lives or statins lower blood sugars. If this be law, we would have very few drugs and lots of sick patients.

Previous Page : 1 2 3 4 5 6 7 Next11 to 20 of 68

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T09:45:16.440